KELOWNA, BC / ACCESSWIRE / August 3, 2023 / Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce the appointment of Australia-based Jason Carroll as the Company's new Chief Executive Officer, beginning October 1, 2023. Mr. Carroll brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb. Mr. Carroll remarked, "I am thrilled to begin building on the solid foundation laid by the Tryp Therapeutics team. With positive clinical data in Binge Eating Disorder and two open INDs for the conduct of chronic pain studies at Massachusetts General Hospital, Harvard University, and University of Michigan, we are remarkably well-positioned to capitalize on the immense opportunities available for the use of psilocybin-based therapies to treat neuropsychiatric disorders." Tryp Therapeutics' Chairman, Mr. Gage Jull, stated, "Jason's broad knowledge of the healthcare space, combined with his multi-disciplinary approach and strategic vision, make him an ideal fit to lead our company forward. His experiences navigating complex healthcare systems in both developed and emerging markets will undoubtedly further our immediate and long-term goals." Mr. Jull continued, "Dr. Jim Gilligan's invaluable stewardship as Tryp's interim CEO during our search has set the stage for the next phase of Tryp's development. We extend our sincere gratitude to Jim for his service and are excited for him to return to his core role as Chief Scientific Officer. With this exceptionally strong executive team in place, we believe Tryp is poised for significant success over the coming months and years." As part of his appointment, Mr. Carroll will be granted an aggregate of 7,713,548 stock options (the "Options"). These Options will be governed in accordance with the terms of the Company's stock option plan, will be subject to certain vesting restrictions, and will be priced at the date of their grant. The Company also announced that its consulting agreement with Mr. Sid Taubenfeld, who was acting as the Company's Chief Operating Officer, has been terminated pursuant to the terms of that agreement. About Tryp Therapeutics Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has initiated a Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida, where an interim analysis showed an average reduction in binge eating episodes of greater than 80%. The Company is also planning for Phase 2a clinical trials with the University of Michigan for the treatment of fibromyalgia and with Mass General Hospital for the treatment of abdominal pain related to irritable bowel syndrome. Each of the studies are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety and patient experience. For more information, please visit . Investor & Media Contact Peter Molloy Chief Business Officer Tryp Therapeutics pmolloy@tryptherapeutics.com Forward-Looking Information Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans," "targets," "expects" or "does not expect," "is expected," "an opportunity exists," "is positioned," "estimates," "intends," "assumes," "anticipates" or "does not anticipate" or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," "will" or "will be taken," "occur" or "be achieved." In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors'' section of Tryp's final prospectus available at . These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. SOURCE: Tryp Therapeutics View source version on accesswire.com:

临床2期高管变更

2023-04-06

·Firstwordpharma

Sources say iNova in talks to buy Mundipharma's OTC unit: report

iNova Pharmaceuticals is said to be in advanced talks to acquire Mundipharma's over-the-counter (OTC) business for a potential value of $700 million, Bloomberg reported Thursday citing people familiar with the matter. Negotiations are ongoing and there is no guarantee that an agreement will be reached, the people said.A report last year indicated that the Sackler family's attempt to sell Mundipharma's Chinese assets for more than $1 billion had stalled after bids failed to meet expectations. The plan to offload Mundipharma China came as the Sacklers offered over $4 billion in a settlement for Purdue Pharma, another drug company they own, to resolve ongoing opioid lawsuits in the US.Mundipharma focuses on pain management, infectious diseases and other serious illnesses. Its consumer health business includes the antiseptic Betadine. Meanwhile, iNova Pharma specialises in distributing a range of pharmacy products and prescription medicines, including brands like Difflam, Duro-Tuss, Demazin and Dequadin.Last year, TPG acquired a majority stake in iNova Pharma, while Pacific Equity Partners re-invested as a minority stakeholder.

并购专利侵权

2023-01-10

·PRNewswire

The Demand for Natural Fertility Supplements is Boosting the Global Fertility Supplement Market. The Demand for Fertility Supplements to Reach Almost USD 3 Billion, A 2X Growth, By 2027 - Arizton

CHICAGO, Jan. 10, 2023 /PRNewswire/ -- According to Arizton's latest research report, the fertility supplements market is likely to grow at a CAGR of 8% during 2021-2027. Factors such as growing awareness regarding fertility health, increasing advanced maternal age population (women) in developed and emerging markets, rapidly increasing infertile couples worldwide, and awareness of infertility issues among the global adult population are boosting the fertility supplements market. Continue Reading Fertility Supplements Market Several global and regional players in the market offer a wide range of fertility supplements in natural, synthetic, and blend ingredients. Consumer preference and better clinical outcomes are increasing the demand for fertility supplements. Most vendors are increasingly focused on marketing and extending their product portfolio to gain a competitive edge over other market players. Rapid advances in the fertility supplement industry have significantly impacted the growth of products. Europe is a highly dominating global fertility supplements market region, valued at USD 610.79 million in 2021. Due to the higher awareness level about fertility care and supplements, high expenditure and acceptance of fertility-boosting solutions are expected to fuel the region's market growth. In addition, the increasing infertility prevalence, changing lifestyle, delayed pregnancy, and increasing maternal age are some factors that led to the increasing infertility issues that drive the high demand for fertility care and accelerate the industry growth. In 2021, Italy accounted for 21.70% of the industry share and was the leading country in Europe. The significant industry growth contributing factors addressed in Italy are the significant development and higher acceptance of fertility care services. Fertility Supplements Market Report Scope Click Here to Download the Free Sample Report Rising Focus on Natural Fertility Supplements Natural vitamin E-based fertility products are vital in boosting fertility and are natural antioxidants. It helps the fertilized egg stay attached to the uterine wall. Moreover, Ashwagandha herbs, Vitex, and adaptogens can boost fertility. Maca is a commonly used fertility aid solution. It contains a high level of p-methoxybenzyl isothiocyanate. In some cases, it helps to increase sperm count concentration. Royal jelly is also a natural fertility supplement that increases testosterone. Olive oil and salmon solutions are natural sources of Coenzyme Q10 that are used to boost lagging fertility. It also helps with the energy production of mitochondria to process and recycle energy effectively. Due to proven results in users, the demand for natural fertility supplements is increasing. In addition, many companies are also involved in increasing their natural fertility supplements-based products. New Product Launches In 2022, the leading market player, Ovaterra, launched two prenatal vitamin supplement products, Advanced Prep 35-39 & Advanced Prenatal, designed for pre, during, and post-pregnancy care. In 2022, Wellbeing Nutrition Indian, the fastest-growing plant-based nutrition company, will launch a SLOW nutraceutical product portfolio. In 2022, the Natalist company launched new products such as fertility supplements for every stage of the reproductive journey. The company launched consumer fertility, pregnancy, and essential postpartum products around 100% plastic neutral, including CoQ10 gummies, prenatal gummies, and other fertility and pregnancy test products. Nua fertility is one of the world-class fertility brands focused on innovation and delivery of world-class fertility products. In 2020, the company launched the fertility supplement, NuaBiome, for women. Click Here to Download the Free Sample Report Key Vendors Coast Science Exeltis USA Fairhaven Health LENUS Pharma GesmbH Vitabiotics Ltd. AdvaCare Pharma Bayer Ag Beli CaDi- Cambridge Diagnostic Imaging Carlson Labs DCMG Laboratories Elan Healthcare Eu Natural Fermenta Biotech FullWell Hera (HeraNow) iNova Pharmaceuticals (Pty) Ltd. Laboratorios Fertypharm S.L. Life Extension Nestlé Nature's Craft Nutra Business Nua Fertility Ocean Healthcare Orthomol Ovaterra Pragati Biocare Pvt. Ltd. Premama Puritan's Pride Ritual Renova Nutrition Supplemena Seeking Health TTK Thorne Wellbeing Nutrition Zenith Nutrition Market Segmentation Form Natural Synthetic & Blend Type Capsule Tablet Soft Gel Powder Liquid Gender Women Men Purchase Channels Over-the-counter (OTC) Prescription Geography North America US Canada Europe Germany Italy Spain France UK APAC Japan China South Korea India Australia Latin America Brazil Mexico Argentina Middle East & Africa Turkey Saudi Arabia South Africa UAE Check Out Some of the Top-Selling Related Research Reports: U.S. Assisted Reproductive Technology Market - The U.S. assisted reproductive technology market is expected to cross $4 billion by 2027. Key players with huge infrastructure and R&D support are expanding their footprint in the industry by implementing various marketing strategies to gain traction among end-users and increase their market presence. U.S. Fertility Test Market - U.S. fertility test market is projected to reach USD 201.4 million in 2027. A fertility test is a procedure by which the fertility of males or females can assess, and search the fertile window during a month. Fertility tests are assessed by ovulation test kits, fertility monitors, and sperm testing. The increasing infertility prevalence and rising maternal age directly impact male and female fertility, driving the demand for fertility tests. The U.S. fertility test market is likely to develop due to favorable demographic and social/cultural shifts due to attractive long-term growth. Fertility Test Market - The global fertility test market is expected to reach USD 659.71 million by 2027. The global fertility treatment is presumably to grow healthy due to attractive long-term growth from favorable demographic and social/cultural shifts. Fertility testing is a niche industry with high margins for manufacturers, especially for vendors offering kits, which males and females widely use. U.S. In-Vitro Fertilization (IVF) Market- The U.S. in-vitro fertilization market is expected to reach USD 231.68 million by 2026. The presence of global, regional, and local vendors characterizes the US in-vitro fertilization market. In recent years, the global infertility treatment market has witnessed many strategic initiatives by key vendors, which is expected to intensify market competitiveness in the upcoming years. Infertility treatment is a niche industry with high margins for manufacturers, especially for vendors offering equipment, media, and related consumables, that are widely used during ART procedures. Table of Content 1 RESEARCH METHODOLOGY 2 RESEARCH OBJECTIVES 3 RESEARCH PROCESS 4 SCOPE & COVERAGE 4.1 MARKET DEFINITION 4.1.1 INCLUSIONS 4.1.2 EXCLUSIONS 4.1.3 MARKET ESTIMATION CAVEATS 4.2 BASE YEAR 4.3 SCOPE OF THE STUDY 4.3.1 MARKET SEGMENTATION BY FORM 4.3.2 MARKET SEGMENTATION BY TYPE 4.3.3 MARKET SEGMENTATION BY GENDER 4.3.4 MARKET SEGMENTATION BY PURCHASE CHANNEL 4.3.5 MARKET SEGMENTATION BY GEOGRAPHY 5 REPORT ASSUMPTIONS & CAVEATS 5.1 KEY CAVEATS 5.2 CURRENCY CONVERSION 5.3 MARKET DERIVATION 6 MARKET AT A GLANCE 7 INTRODUCTION 7.1 OVERVIEW 8 PREMIUM INSIGHTS 8.1 OVERVIEW 9 MARKET OPPORTUNITIES & TRENDS 9.1 ADVANCES, RESEARCH, & CREDIBILITY IN FERTILITY SUPPLEMENTS 9.2 INCREASE IN PRODUCT LAUNCHES 9.3 FOCUS ON NATURAL FERTILITY SUPPLEMENTS 10 MARKET GROWTH ENABLERS 10.1 INCREASE IN PREVALENCE OF INFERTILITY RATE 10.2 INCREASE IN GOVERNMENT & PUBLIC INITIATIVES FOR FERTILITY AWARENESS 10.3 TREND OF DELAYED PREGNANCIES 11 MARKET RESTRAINTS 11.1 LACK OF AWARENESS & LOW ACCESS TO FERTILITY TREATMENTS IN EMERGING MARKETS 11.2 SIDE EFFECTS RELATED TO FERTILITY SUPPLEMENTS 11.3 PRESENCE OF ALTERNATIVES TO FERTILITY SUPPLEMENTS 12 MARKET LANDSCAPE 12.1 MARKET OVERVIEW 12.1.1 INSIGHT BY GEOGRAPHY 12.1.2 INSIGHT BY PURCHASE CHANNEL 12.1.3 INSIGHT BY FORM 12.1.4 INSIGHT BY TYPE 12.1.5 INSIGHTS BY GENDER 12.2 MARKET SIZE & FORECAST 12.3 FIVE FORCES ANALYSIS 12.3.1 THREAT OF NEW ENTRANTS 12.3.2 BARGAINING POWER OF SUPPLIERS 12.3.3 BARGAINING POWER OF BUYERS 12.3.4 THREAT OF SUBSTITUTES 12.3.5 COMPETITIVE RIVALRY 13 FORM 13.1 MARKET SNAPSHOT & GROWTH ENGINE 13.2 MARKET OVERVIEW 13.3 NATURAL 13.3.1 MARKET OVERVIEW 13.3.2 MARKET SIZE & FORECAST 13.3.3 MARKET BY GEOGRAPHY 13.4 SYNTHETIC & BLEND 13.4.1 MARKET OVERVIEW 13.4.2 MARKET SIZE & FORECAST 13.4.3 MARKET BY GEOGRAPHY 14 TYPE 14.1 MARKET SNAPSHOT & GROWTH ENGINE 14.2 MARKET OVERVIEW 14.3 CAPSULE 14.3.1 MARKET OVERVIEW 14.3.2 MARKET SIZE & FORECAST 14.3.3 MARKET BY GEOGRAPHY 14.4 TABLET 14.4.1 MARKET OVERVIEW 14.4.2 MARKET SIZE & FORECAST 14.4.3 MARKET BY GEOGRAPHY 14.5 SOFT GEL 14.5.1 MARKET OVERVIEW 14.5.2 MARKET SIZE & FORECAST 14.5.3 MARKET BY GEOGRAPHY 14.6 POWDER 14.6.1 MARKET OVERVIEW 14.6.2 MARKET SIZE & FORECAST 14.6.3 MARKET BY GEOGRAPHY 14.7 LIQUID 14.7.1 MARKET OVERVIEW 14.7.2 MARKET SIZE & FORECAST 14.7.3 MARKET BY GEOGRAPHY 15 GENDER 15.1 MARKET SNAPSHOT & GROWTH ENGINE 15.2 MARKET OVERVIEW 15.3 WOMEN 15.3.1 MARKET OVERVIEW 15.3.2 MARKET SIZE & FORECAST 15.3.3 MARKET BY GEOGRAPHY 15.4 MEN 15.4.1 MARKET OVERVIEW 15.4.2 MARKET SIZE & FORECAST 15.4.3 MARKET BY GEOGRAPHY 16 PURCHASE CHANNEL 16.1 MARKET SNAPSHOT & GROWTH ENGINE 16.2 MARKET OVERVIEW 16.3 OVER-THE-COUNTER (OTC) 16.3.1 MARKET OVERVIEW 16.3.2 MARKET SIZE & FORECAST 16.3.3 MARKET BY GEOGRAPHY 16.4 PRESCRIPTION 16.4.1 MARKET OVERVIEW 16.4.2 MARKET SIZE & FORECAST 16.4.3 MARKET BY GEOGRAPHY 17 GEOGRAPHY 17.1 MARKET SNAPSHOT & GROWTH ENGINE 17.2 GEOGRAPHIC OVERVIEW 18 EUROPE 18.1 MARKET OVERVIEW 18.2 MARKET SIZE & FORECAST 18.3 FORM 18.3.1 MARKET SIZE & FORECAST 18.4 TYPE 18.4.1 MARKET SIZE & FORECAST 18.5 GENDER 18.5.1 MARKET SIZE & FORECAST 18.6 PURCHASE CHANNEL 18.6.1 MARKET SIZE & FORECAST 18.7 KEY COUNTRIES 18.7.1 ITALY: MARKET SIZE & FORECAST 18.7.2 SPAIN: MARKET SIZE & FORECAST 18.7.3 GERMANY: MARKET SIZE & FORECAST 18.7.4 UK: MARKET SIZE & FORECAST 18.7.5 FRANCE: MARKET SIZE & FORECAST 19 NORTH AMERICA 19.1 MARKET OVERVIEW 19.2 MARKET SIZE & FORECAST 19.3 FORM 19.3.1 MARKET SIZE & FORECAST 19.4 TYPE 19.4.1 MARKET SIZE & FORECAST 19.5 GENDER 19.5.1 MARKET SIZE & FORECAST 19.6 PURCHASE CHANNEL 19.6.1 MARKET SIZE & FORECAST 19.7 KEY COUNTRIES 19.7.1 US: MARKET SIZE & FORECAST 19.7.2 CANADA: MARKET SIZE & FORECAST 20 APAC 20.1 MARKET OVERVIEW 20.2 MARKET SIZE & FORECAST 20.3 FORM 20.3.1 MARKET SIZE & FORECAST 20.4 TYPE 20.4.1 MARKET SIZE & FORECAST 20.5 GENDER 20.5.1 MARKET SIZE & FORECAST 20.6 PURCHASE CHANNEL 20.6.1 MARKET SIZE & FORECAST 20.7 KEY COUNTRIES 20.7.1 JAPAN: MARKET SIZE & FORECAST 20.7.2 CHINA: MARKET SIZE & FORECAST 20.7.3 INDIA: MARKET SIZE & FORECAST 20.7.4 SOUTH KOREA: MARKET SIZE & FORECAST 20.7.5 AUSTRALIA: MARKET SIZE & FORECAST 21 LATIN AMERICA 21.1 MARKET OVERVIEW 21.2 MARKET SIZE & FORECAST 21.3 FORM 21.3.1 MARKET SIZE & FORECAST 21.4 TYPE 21.4.1 MARKET SIZE & FORECAST 21.5 GENDER 21.5.1 MARKET SIZE & FORECAST 21.6 PURCHASE CHANNEL 21.6.1 MARKET SIZE & FORECAST 21.7 KEY COUNTRIES 21.7.1 BRAZIL: MARKET SIZE & FORECAST 21.7.2 MEXICO: MARKET SIZE & FORECAST 21.7.3 ARGENTINA: MARKET SIZE & FORECAST 22 MIDDLE EAST & AFRICA 22.1 MARKET OVERVIEW 22.2 MARKET SIZE & FORECAST 22.3 FORM 22.3.1 MARKET SIZE & FORECAST 22.4 TYPE 22.4.1 MARKET SIZE & FORECAST 22.5 GENDER 22.5.1 MARKET SIZE & FORECAST 22.6 PURCHASE CHANNEL 22.6.1 MARKET SIZE & FORECAST 22.7 KEY COUNTRIES 22.7.1 TURKEY: MARKET SIZE & FORECAST 22.7.2 SAUDI ARABIA: MARKET SIZE & FORECAST 22.7.3 SOUTH AFRICA: MARKET SIZE & FORECAST 22.7.4 UAE: MARKET SIZE & FORECAST 23 COMPETITIVE LANDSCAPE 23.1 COMPETITION OVERVIEW 23.2 MARKET SHARE ANALYSIS 23.2.1 COAST SCIENCE 23.2.2 EXELTIS USA 23.2.3 FAIRHAVEN HEALTH 23.2.4 LENUS PHARMA GESMBH 23.2.5 VITABIOTICS 24 KEY COMPANY PROFILES 24.1 COAST SCIENCE 24.1.1 BUSINESS OVERVIEW 24.1.2 PRODUCT OFFERINGS 24.1.3 KEY STRATEGIES 24.1.4 KEY STRENGTHS 24.1.5 KEY OPPORTUNITIES 24.2 EXELTIS USA 24.3 FAIRHAVEN HEALTH 24.4 LENUS PHARMA GESMBH 24.5 VITABIOTICS 25 OTHER PROMINENT VENDORS 25.1 ADVACARE PHARMA 25.1.1 BUSINESS OVERVIEW 25.1.2 PRODUCT OFFERINGS 25.2 BAYER AG 25.3 BELI 25.4 CADI - CAMBRIDGE DIAGNOSTIC IMAGING 25.5 CARLSON LABS 25.6 DCMG LABORATORIES 25.7 ELAN HEALTHCARE 25.8 EU NATURAL 25.9 FERMENTA BIOTECH 25.10 FULLWELL 25.11 HERA (HERANOW) 25.12 INOVA PHARMACEUTICALS (PTY) LTD. 25.13 LABORATORIOS FERTYPHARM S.L. 25.14 LIFE EXTENSION 25.15 NESTLÉ 25.16 NATURE'S CRAFT 25.17 NUTRA BUSINESS 25.18 NUA FERTILITY 25.19 OCEAN HEALTHCARE 25.20 ORTHOMOL 25.21 OVATERRA 25.22 PRAGATI BIOCARE PVT. LTD. 25.23 PREMAMA 25.24 PURITAN'S PRIDE 25.25 RITUAL 25.26 RENOVA NUTRITION 25.27 SUPPLEMENA 25.28 SEEKING HEALTH 25.29 TTK 25.30 THORNE 25.31 WELLBEING NUTRITION 25.32 ZENITH NUTRITION 26 REPORT SUMMARY 26.1 KEY TAKEAWAYS 26.2 STRATEGIC RECOMMENDATIONS 27 QUANTITATIVE SUMMARY 27.1 MARKET BY GEOGRAPHY 27.2 MARKET BY FORM 27.3 MARKET BY TYPE 27.4 MARKET BY GENDER 27.5 MARKET BY PURCHASE CHANNEL 27.6 FORM: MARKET BY GEOGRAPHY 27.6.1 NATURAL: MARKET BY GEOGRAPHY 27.6.2 SYNTHETIC & BLEND: MARKET BY GEOGRAPHY 27.7 TYPE: MARKET BY GEOGRAPHY 27.7.1 CAPSULE: MARKET BY GEOGRAPHY 27.7.2 TABLET: MARKET BY GEOGRAPHY 27.7.3 SOFT GEL: MARKET BY GEOGRAPHY 27.7.4 POWDER: MARKET BY GEOGRAPHY 27.7.5 LIQUID: MARKET BY GEOGRAPHY 27.8 GENDER: MARKET BY GEOGRAPHY 27.8.1 WOMEN: MARKET BY GEOGRAPHY 27.8.2 MEN: MARKET BY GEOGRAPHY 27.9 PURCHASE CHANNEL: MARKET BY GEOGRAPHY 27.9.1 OTC: MARKET BY GEOGRAPHY 27.9.2 PRESCRIPTION: MARKET BY GEOGRAPHY 28 APPENDIX 28.1 ABBREVIATIONS About Us :  Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  Click Here to Contact Us  Call: +1-312-235-2040            +1 302 469 0707  Mail: [email protected] Photo: Logo: SOURCE Arizton Advisory & Intelligence